• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Wednesday, August 6, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

MCRI’s BCG vaccine trial joins global race to better understand COVID-19 variants

Bioengineer by Bioengineer
June 8, 2021
in Health
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

IMAGE

Credit: Bermix Studio

An Australian-led study will investigate whether it’s possible to predict who remains susceptible to SARS-CoV-2 variants after having COVID-19 or receiving a COVID-19-specific vaccine.

The study will explore the immune response to COVID-19-specific vaccines in Brazilian healthcare workers to find biomarkers that indicate whether someone will be protected from – or remains at risk of – contracting COVID-19 if exposed to a variant.

The research has received philanthropic funding from the Bill & Melinda Gates Foundation and is a sub-study of the Murdoch Children’s Research Institute’s (MCRI) study assessing if the Bacille Calmette-GuĂ©rin (BCG) vaccine can help protect against COVID-19.

The BRACE trial is now the world’s largest study on the off-target effects of the BCG vaccine. Since the trial launched in March 2020, more than 6800 healthcare workers have enrolled across 36 sites in Australia, Brazil, the Netherlands, Spain and the UK.

BCG was originally developed 100 years ago to prevent tuberculosis. Now, the BRACE randomised controlled clinical trial is working to determine if the BCG vaccine reduces the incidence of symptomatic and severe COVID-19 in healthcare workers. It is also investigating whether BCG vaccine reduces the impact of other respiratory illnesses and allergic diseases.

Professor Nigel Curtis, Head of the Infectious Diseases Research Group at MCRI, Professor of Paediatric Infectious Diseases at the University of Melbourne and BRACE Chief Principal Investigator, said the big story of 2021 was the potential impact of SARS-CoV-2 variants.

“With the emergence of new variants – for which vaccine-induced and natural immune responses may not be as effective – there is concern that herd immunity may be undermined. If this happens, SARS-CoV-2 will continue to spread and cause disease,” he said.

“We have been lucky enough to receive this additional funding for the BRACE COVID-19-Specific vaccine sub-study (BCOS) to investigate biomarkers of protection against SARS-CoV-2 infection and reinfection induced by natural infection and COVID-specific vaccination.”

Associate Professor Julio Croda, the BRACE trial’s Brazil Principal Investigator, said 2400 healthcare workers across three trial sites in Brazil were being actively followed up and tested for COVID-19 as part of the trial.

“This subset of participants provides a unique opportunity to understand the risks and determinants of susceptibility to reinfection with SARS-CoV-2 variants, particularly the P.1 variant. This research is critical to designing effective approaches to help protect people,” he said.

With COVID-19-specific vaccines now available to healthcare workers, BCOS will also look at whether BCG vaccine improves the immune response to Pfizer, AstraZeneca and CoronaVac vaccines.

Dr Nicole Messina, the Biosample and Laboratory Lead on the BRACE trial said: “We are recruiting existing BRACE trial participants in Victoria, South Australia and Brazil to assess whether those who had the BCG vaccine have a better or more prolonged immune response to their COVID-19-specific vaccine.”

Professor Kathryn North AM, MCRI Director, said: “It’s incredibly exciting work and demonstrates how MCRI responded to the pandemic. A deeper understanding of immune responses to COVID-19-specific vaccines will be important to the global effort to contain this pandemic.”

Participant follow-up continues every three months with questionnaires and blood collection, as well as ongoing data collection via phone calls and the trial’s custom-built smartphone app, powered by WeGuide.

The BRACE trial has received philanthropic funding from the Bill & Melinda Gates Foundation, Sarah and Lachlan Murdoch, Minderoo Foundation, The Royal Children’s Hospital Foundation, South Australian government, NAB Foundation, The Calvert Jones Foundation, UHG Foundation, Modara Pines Charitable Foundation, Health Services Union NSW, Peter Sowerby Foundation, South Australia Ministry of Health, Epworth Health, Swiss National Science Foundation and individual donors.

###

BRACE audio grabs, video and images available for download

Available for interview

Professor Nigel Curtis

BRACE trial Chief Principal Investigator

Head of the Infectious Diseases Research Group at the Murdoch Children’s Research Institute

Professor of Paediatric Infectious Diseases at The University of Melbourne

Head of Infectious Diseases at The Royal Children’s Hospital Melbourne

Dr Nicole Messina

Biosample and Laboratory Lead on the BRACE trial at the Murdoch Children’s Research Institute

Honorary Fellow, Department of Paediatrics, Melbourne Medical School at The University of Melbourne

Media Contact
Harriet Edmund
[email protected]

Tags: Infectious/Emerging DiseasesMedicine/HealthVaccines
Share12Tweet8Share2ShareShareShare2

Related Posts

Real-Time Imaging Reveals Caspase Dynamics and Immunogenic Death

Real-Time Imaging Reveals Caspase Dynamics and Immunogenic Death

August 6, 2025
Predicting Time of Death Using Organ Metabolites

Predicting Time of Death Using Organ Metabolites

August 6, 2025

Mapping Mood and Substance Use in Urban Teens

August 6, 2025

Early Pregnancy Depression Linked to Toddler Allergies

August 6, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Neuropsychiatric Risks Linked to COVID-19 Revealed

    74 shares
    Share 30 Tweet 19
  • Overlooked Dangers: Debunking Common Myths About Skin Cancer Risk in the U.S.

    61 shares
    Share 24 Tweet 15
  • Predicting Colorectal Cancer Using Lifestyle Factors

    46 shares
    Share 18 Tweet 12
  • Dr. Miriam Merad Honored with French Knighthood for Groundbreaking Contributions to Science and Medicine

    47 shares
    Share 19 Tweet 12

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Prenatal Antibiotics Impact Breast Milk, Neonatal Immunity

Real-Time Imaging Reveals Caspase Dynamics and Immunogenic Death

Predicting Time of Death Using Organ Metabolites

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.